EP0941226A1 - (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase - Google Patents

(2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase

Info

Publication number
EP0941226A1
EP0941226A1 EP97952758A EP97952758A EP0941226A1 EP 0941226 A1 EP0941226 A1 EP 0941226A1 EP 97952758 A EP97952758 A EP 97952758A EP 97952758 A EP97952758 A EP 97952758A EP 0941226 A1 EP0941226 A1 EP 0941226A1
Authority
EP
European Patent Office
Prior art keywords
hydrogen
hydroxy
mono
alkoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97952758A
Other languages
German (de)
English (en)
Inventor
Hermann Amschler
Thomas Martin
Dieter Flockerzi
Beate Gutterer
Karl-Josef Goebel
Armin Hatzelmann
Hildegard Boss
Dietrich Häfner
Hans-Peter Kley
Rolf Beume
Thomas Bär
Wolf-Rüdiger Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG, Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Altana Pharma AG
Priority to EP97952758A priority Critical patent/EP0941226A1/fr
Publication of EP0941226A1 publication Critical patent/EP0941226A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention relates to new thiazole derivatives which are used in the pharmaceutical industry for the manufacture of medicaments.
  • Japanese patent JP 46-15935 describes substituted 4- (carboxyphenyl) thiazoles and their use for the treatment of thrombosis, arteriosclerosis, gastric ulcers and hypersecretion.
  • European patent applications EP 0 513 387 and EP 0 600 092 describe, inter alia, 4- (substituted phenyl) thiazole derivatives, 4- (substituted 2,3-dihydrobenzofuran) thiazole derivatives and their use as inhibitors of oxygen radical release by neutrophils. The compounds are therefore described as being suitable for the treatment of acute inflammatory processes such as ischemia and reperfusion damage.
  • the invention thus relates to compounds of the formula I (see attached formula sheet I), in which
  • R1 is hydroxy, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or completely or predominantly fluorine-substituted 1-4C-alkoxy
  • R2 is hydrogen or 1-4C-alkyl
  • R3 is hydrogen or 1- 4C-alkyl means or R2 and R3 together and including the two carbon atoms to which they are attached represent a 5-, 6- or 7-membered hydrocarbon ring, optionally interrupted by an oxygen atom,
  • R4 represents a phenyl or naphthyl ring substituted by R41, R42 and R43, represents a mono- or bicyclic heterocycle substituted by R44, R45 and R46, which is selected from the group pyridine, pyrrole, quinoline, isoquinoline, indole, isoindole, indolizine, Pyrimidine, pyrazine, pyridazine, quinoxaline, quinazoline, cinnoline, benzimidazole, thiophene and furan or a mono- or bicyclic heterocycle substituted by R44 and R45, which is selected from the group pyrazole, imidazole, purine, oxazole, isoxazole, thiazole and isothiazole, wherein
  • R41 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkylsulfonyl, 1-4C-alkoxysulfonyl, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, halogen, cyano or nitro,
  • R42 hydrogen, wholly or predominantly fluorine-substituted 1-4C-alkoxy, hydroxy, amino, nitro, halogen, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkyicarbonyl, carboxyl, 1-4C-alkyl or 1 -4C-alkoxy,
  • R43 is hydrogen, 1-4C-alkoxy, halogen or hydroxy
  • R44 hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, halogen, cyano or nitro,
  • R45 is hydrogen, hydroxy, halogen, carboxyl, amino, 1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkoxycarbonyl or 1-4C-alkoxy and
  • R46 is hydrogen, halogen, 1-4C-alkoxy or 1-4C-alkyl
  • R5 is hydrogen or halogen, n is 0, 1 or 2, the salts of these compounds and the N-oxides of pyridines, quinolines, isoquinolines, pyrimidines,
  • 1-4C-Alkyl stands for straight-chain or branched alkyl radicals with 1 to 4 carbon atoms. Examples include the butyl, iso-butyl, sec-butyl, tert-butyl, propyl, iso-propyl, ethyl and methyl radicals.
  • 1-4C-alkoxy stands for a radical which, in addition to the oxygen atom, contains one of the above-mentioned straight-chain or branched alkyl radicals having 1 to 4 carbon atoms.
  • alkoxy residues with 1 up to 4 carbon atoms may be mentioned here, for example, butoxy, iso-butoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy, ethoxy and methoxy.
  • 3-7C-Cycloalkoxy stands for the cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy radical.
  • the 3-5C-cycloalkoxy radicals cyclopropyloxy, cyclobutyloxy and cyclopentyloxy are preferred.
  • 3-7C-Cycloalkylmethoxy stands for Cyclopropylmethoxy, Cyclobutylmethoxy, Cyclopentylmethoxy, Cyclohexylmethoxy and Cycloheptylmethoxy.
  • the 3-5C-cycloalkylmethoxy radicals cyclopropylmethoxy, cyclobutylmethoxy and cyclopentylmethoxy may be mentioned as preferred.
  • the cyclopentane, the cyclohexane, the cycloheptane, the tetrahydrofuran and the tetrahydropyran ring may be mentioned as a 5-, 6- or 7-membered hydrocarbon ring, optionally interrupted by an oxygen atom. If R2 and R3 together and including the two carbon atoms to which they are attached form a 5-, 6- or 7-membered ring, a spiro compound is present.
  • Halogen in the sense of the invention is fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
  • Examples of mono- or di-1-4C-alkylamino radicals are the methylamino, the dimethylamino, the ethylamino, the diethylamino, the propylamino and the isopropylamino radical.
  • Mono- or di-1-4C-alkylaminocarbonyl stands for a carbonyl group to which one of the abovementioned mono- or di-1-4C-alkylamino radicals is attached.
  • the methylaminocarbonyl, dimethylaminocarbonyl and ethylaminocarbonyl radicals may be mentioned as examples.
  • Mono- or di-1-4C-alkylaminosulfonyl stands for a sulfonyl group to which one of the abovementioned mono- or di-1-4C-alkylamino residues is bonded.
  • the methylaminosulfonyl, the dimethylaminosulfonyl and the ethylaminosulfonyl radical may be mentioned by way of example.
  • the 1-4C-alkylcarbonylamino radical may be mentioned, for example, the acetylamino radical (-NH-CO-CH 3 ).
  • 1-4C-alkoxycarbonyl stands for a carbonyl group to which one of the above-mentioned 1-4C-alkoxy radicals is attached. Examples include methoxycarbonyl (CH 3 O-CO-) and ethoxycarbonyl (CH 3 CH 2 0-CO-).
  • 1-4C-alkylcarbonyl stands for a carbonyl group to which one of the above-mentioned 1-4C-alkyl radicals is attached.
  • the acetyl radical (CH 3 CO-) may be mentioned.
  • 1-4C-alkylcarbonyloxy radicals contain a 1-4C-alkylcarbonyl radical.
  • the acetoxy residue (CH 3 CO-O-) may be mentioned.
  • Hydroxy-1-4C-alkyl stands for the aforementioned 1-4C-alkyl radicals which are substituted by a hydroxyl group.
  • the hydroxyethyl and hydroxymethyl radicals may be mentioned.
  • 1-4C-Alkylsulfonyl stands for a sulfonyl group to which one of the above-mentioned 1-4C-alkyl radicals is attached.
  • the methylsulfonyl radical (CH 3 S0 2 -) may be mentioned.
  • 1-4C-alkoxysulfonyl stands for a sulfonyl group to which one of the above-mentioned 1-4C-alkoxy radicals is attached. Examples include the methoxysulfonyl (CH 3 0-S0 2 -) and ethoxysulfonyl (CH 3 CH 2 0-S0 2 -) groups.
  • the substituent R4 can be attached to the rest of the compounds of the formula I via any suitable ring position of the phenyl or naphthyl ring or of the heterocycle, the attachment of the heterocycles not taking place via a ring heteroatom.
  • R4 are phenyl, 3,4-dihydroxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,5-dimethoxyphenyl, 2,3-dimethoxyphenyl, 2,4-dimethoxyphenyl, 3- Methoxy-4-hydroxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-ethoxycarbonylphenyl, 3,4-diethoxyphenyl, 3,4-dimethylphenyl, 4-fluorophenyl, 3-chloro-4- methylphenyl, 3-nitrophenyl, 3,4-dichlorophenyl, 4-bromophenyl, 3,4-dibutoxyphenyl, 3,4-dipropoxyphenyl, 3-ethoxy-4-methoxyphenyl, 3-bromo-4,5-dimethoxyphenyl, 3,4-diacetoxyphenyl, 4-dimethyla
  • Suitable salts for compounds of the formula I - depending on the substitution - are all acid addition salts or all salts with bases. Particular mention should be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases commonly used in galenics.
  • Suitable as such are on the one hand water-soluble and water-insoluble acid addition salts with acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, maleic acid , Lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, the acids in the salt production - depending on whether it is a mono- or poly-based acid and, depending on which salt is desired, be used in an equimolar or a different quantity ratio.
  • acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid,
  • salts with bases can also be used.
  • alkali lithium, sodium, potassium
  • calcium, aluminum, magnesium, titanium, ammonium, meglumine or guanidinium salts may be mentioned, the bases also being used here in salt production equimolar or a different ratio.
  • Pharmacologically incompatible salts which may initially be obtained as process products in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically acceptable salts by processes known to the person skilled in the art.
  • R1 is 1-4C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,
  • R3 is hydrogen or 1-4C-alkyl
  • R2 and R3 together and including the two carbon atoms to which they are attached represent a cyclopentane, cyclohexane, tetrahydrofuran or tetrahydropyran ring,
  • R4 represents a phenyl ring substituted by R41 and R42 or represents a mono- or bicyclic heterocycle substituted by R44 and R45, which is selected from the group pyridine, pyrrole, quinoline, isoquinoline, indole, isoindole, indolizine, pyrimidine, pyrazine, pyridazine, pyrazole , Imidazole, quinoxaline, quinazoline, cinnoline, benzimidazole, oxazole, isoxazole, thiazole and isothiazole, where R41 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamin
  • R42 is hydrogen, hydroxy, nitro, halogen, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkylcarbonyl, carboxyl or 1-4C-alkoxy,
  • R44 hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, halogen or cyano and
  • R45 is hydrogen, hydroxy, halogen, carboxyl, amino, 1-4C-alkyl or 1-4C-alkoxy,
  • R5 is hydrogen or halogen, n is 0 or 1, the salts of these compounds and the N-oxides of pyridines, quinolines, isoquinolines, pyrimidines,
  • R1 is 1-4C-alkoxy, 3-5C-cycloalkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy,
  • R2 and R3 together and including the two carbon atoms to which they are attached represent a cyclopentane or cyclohexane ring,
  • R4 represents a phenyl ring substituted by R41 and R42 or represents a mono- or bicyclic heterocycle substituted by R44 and R45, which is selected from the group pyridine, pyrrole, quinoline, isoquinoline, indole, isoindole, indolizine and pyrazine, where
  • R41 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkylsulfonyl, 1-4C-alkoxysulfonyl, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, halogen, cyano or nitro,
  • R42 is hydrogen, hydroxy, nitro, halogen, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkylcarbonyl, carboxyl or 1-4C-alkoxy,
  • R44 hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, halogen or cyano and
  • R45 is hydrogen, hydroxy, halogen, carboxyl, amino, 1-4C-alkyl or 1-4C-alkoxy,
  • R5 means hydrogen n 0 means the salts of these compounds and the N-oxides of pyridines, quinolines and isoquinolines and their
  • Preferred compounds of formula I are those in which
  • R1 is 1-4C-alkoxy or completely or predominantly fluorine-substituted 1-2C-alkoxy
  • R2 and R3 together and including the two carbon atoms to which they are attached form a cyclopentane ring
  • R4 represents a phenyl ring substituted by R41 and R42 or represents pyridine or pyrazine substituted by R44 and R45, where
  • R41 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, 1-4C-alkylsulfonyl, 1-4C-alkoxysulfonyl, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, halogen, cyano or nitro,
  • R42 is hydrogen, hydroxy, nitro, halogen, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyloxy, 1-4C-alkylcarbonyl, carboxyl or 1-4C-alkoxy,
  • R44 hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C- alkylamino, 1-4C-alkylcarbonylamino, hydroxy-1-4C-alkyl, hydroxy, 1-4C-alkoxy, 1-4C-alkyl, 1-4C-alkylcarbonyl, halogen or cyano and
  • R45 is hydrogen, hydroxy, halogen, carboxyl, amino, 1-4C-alkyl or 1-4C-alkoxy,
  • R5 is hydrogen, n is 0, the salts of these compounds and the N-oxides of pyridines and their salts.
  • R1 is 1-4C-alkoxy
  • R2 and R3 together and including the two carbon atoms to which they are attached form a cyclopentane ring
  • R4 represents a phenyl ring substituted by R41 or represents pyridine substituted by R44, where
  • R41 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl or hydroxy and
  • R44 is hydrogen, carboxyl, 1-4C-alkoxycarbonyl, carbamoyl, hydroxysulfonyl, sulfamoyl or hydroxy,
  • R5 means hydrogen, n means 0, as well as the salts of these compounds.
  • R1 means methoxy
  • R2 and R3 together and including the two carbon atoms to which they are attached form a cyclopentane ring
  • R4 represents a phenyl ring substituted by R41 or represents pyridine substituted by R44, where
  • R44 is hydrogen, carboxyl or 1-4C-alkoxycarbonyl
  • R5 is hydrogen, n is 0, and the salts of these compounds.
  • substitutions -R2 and -CH 2 R3 are not identical, the compounds of the formula I are chiral compounds.
  • the invention therefore encompasses both the pure enantiomers and their mixtures in any mixing ratio, including the racemates.
  • the enantiomers can be separated in a manner known per se (for example by preparing and separating corresponding diastereoisomeric compounds).
  • Compounds of the formula I with identical substitutions -R2 and -CH 2 R3 are preferred.
  • the invention further relates to a process for the preparation of the compounds of the formula I and their salts.
  • the process is characterized in that compounds of the formula II (see attached formula sheet I) in which R1, R2, R3 and R5 have the meanings indicated above and Y is a suitable leaving group with compounds of the formula III (see attached formula sheet I) , in which R4 and n have the meanings given above and Z represents the group -C (S) -NH 2 , and that, if desired, subsequently obtained compounds of the formula I in their salts or, if desired, subsequently obtained salts of the compounds of the Formula I converted into the free compounds.
  • Suitable solvents are, for example, alcohols such as methanol, ethanol or propanol, cyclic hydrocarbons such as toluene or xylene, ethers such as diethyl ether, tetrahydrofuran or dioxane, halogenated hydrocarbons such as dichloromethane or chloroform, polar solvents such as dimethylformamide, acetonitrile or dimethyl sulfoxide or, if desired, mixtures of the solvents mentioned.
  • Preferred bases that are used are nitrogen bases such as triethylamine, ethyldiisopropylamine, N-methylmorpholine or pyridine. The bases can be added in an equimolar ratio (based on compounds of the formula III) or preferably in excess.
  • compounds of the formula I obtained can also be converted into other compounds of the formula I by using methods known to those skilled in the art.
  • the preparation of carboxamides of the formula I from the corresponding carboxylic acids of the formula I may be mentioned as an example.
  • the carboxylic acids of the formula I can be reacted with suitable amines in a manner known to those skilled in the art for the synthesis of carboxamides.
  • the carboxylic acid of the formula I is converted into a suitably activated derivative, for example a corresponding acid halide, before the aminolysis.
  • suitable amines which can be used are ammonia, methylamine or ethylamine.
  • quinolines, isoquinolines, pyrimidines, pyrazines, imidazoles, quinoxalines, quinazolines, benzimidazoles and in particular pyridines of the formula I obtained can also be converted into the corresponding N-oxides or their salts.
  • the N-oxidation takes place in a manner also familiar to the person skilled in the art, e.g. with the help of m-chloroperoxibenzoic acid in dichloromethane at room temperature.
  • the person skilled in the art is familiar with the reaction conditions which are required for carrying out the process in detail on the basis of his specialist knowledge.
  • the substances according to the invention are isolated and purified in a manner known per se, e.g. such that the solvent is distilled off in vacuo and the residue obtained is recrystallized from a suitable solvent or subjected to one of the customary purification methods, such as, for example, column chromatography on a suitable carrier material.
  • Salts are obtained by dissolving the free compound in a suitable solvent, for example in a chlorinated hydrocarbon such as methylene chloride or chloroform, or in a low molecular weight laren aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
  • a suitable solvent for example in a chlorinated hydrocarbon such as methylene chloride or chloroform, or in a low molecular weight laren aliphatic alcohol (ethanol, isopropanol), which contains the desired acid or base, or to which the desired acid or base is then added.
  • the salts are obtained by filtration, reprecipitation, precipitation with a non-solvent for the addition salt or by evaporation of the solvent.
  • Salts obtained can be converted into the free compounds by alkalization or acidification, which in turn can be converted into salts. In this way, pharmacologically incompatible salts can be converted into pharmacologically acceptable salts.
  • the compounds of the formula II in which R1, R2 and R3 have the meanings indicated above, R5 and Y represent hydrogen, can be obtained by reacting compounds of the formula IV (see attached formula sheet I) in which R1, R2 and R3 have the meanings indicated above have and A represents a nitrile group (-CN), with compounds of the formula CH 3 -Mg-X, in which X is halogen, in particular chlorine or bromine, are prepared.
  • the compounds of the formula III, in which R4 and n have the meanings given above and Z represents the group —C (S) —NH 2 are either known (for example from EP 0 513 387 or EP 0 600 092) or can be analogous or other ways known to the person skilled in the art, for example by adding hydrogen sulfide to corresponding compounds of the formula III in which Z is cyano (-CN) [W. Christ, D. Rakow, S. Strauss, J. Heterocycl. Chem. 11, 397 (1974)].
  • Z denotes cyano
  • Z can be described as described in the literature [for example analogously to T. Savaie, T. Ishiguro, K. Kawashima, K. Morita; Tetrahedron Lett. 1973, 2121-2124] from the corresponding compounds of formula III, in which Z is carbamoyl [-C (0) -NH 2 ].
  • the compounds of the formula IV in which A is carbamoyl can be prepared from the compounds of the formula IV in which A is carboxyl in a manner familiar to the person skilled in the art, for example as described in the examples below.
  • a further variant for the preparation of compounds of the formula II in which R1, R2, R3 and R5 have the meanings indicated above and Y represents hydrogen is the reaction of compounds of the formula IV in which R1, R2 and R3 have the meanings indicated above and A is lithium, with compounds of the formula R5-CH 2 -C (0) W, where R5 has the meaning given above and W is a suitable leaving group.
  • Particularly suitable leaving groups W are, for example, halogens, in particular chlorine or bromine or also 1-4C aikoxy radicals.
  • mp stands for melting point, h for hour (s), RT for room temperature, min for minute (s), THF for tetrahydrofuran, DMF for dimethylformamide, Toi. for toluene, EA for ethyl acetate, TLC for thin layer chromatography and PE for petroleum ether.
  • THF tetrahydrofuran
  • DMF dimethylformamide
  • EA ethyl acetate
  • TLC thin layer chromatography
  • PE petroleum ether.
  • the phases are separated, the aqueous phase is extracted with 2 ⁇ 70 ml of ethyl acetate, and the combined organic phases are washed again with 100 ml of water, 100 ml of saturated sodium bicarbonate solution and 100 ml of saturated NaCl solution. It is dried over magnesium sulfate, concentrated and 11.0 g (96%) of the title compound are obtained, which is used for the synthesis of compound A without further purification.
  • the compounds according to the invention have valuable pharmacological properties which make them commercially usable.
  • PDE selective cyclic nucleotide phosphodiesterase
  • they are suitable on the one hand as bronchial therapeutics (for the treatment of airway obstructions due to their dilating but also due to their respiratory rate or respiratory drive increasing effect) and for the eradication of erectile dysfunction due to the vasodilating effect, on the other hand, however, primarily for the treatment of diseases, in particular inflammatory in nature, for example the respiratory tract (asthma prophylaxis), the skin, the intestine, the eyes and the joints, which are mediated by mediators such as histamine, PAF (platelet activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines , alpha, beta and gamma interferon, tumor necrosis factor (TNF) or oxygen radicals and protea
  • mediators such
  • the compounds according to the invention can be used as therapeutic agents in human and veterinary medicine, for example they can be used for the treatment and prophylaxis of the following diseases: Acute and chronic (in particular inflammatory and allergen-induced) respiratory diseases of various origins (bronchitis, allergic Bronchitis, bronchial asthma); Dermatoses (especially proliferative, inflammatory and allergic) such as psoriasis (vulgaris), toxic and allergic contact dermatitis, atopic eczema, seborrheic eczema, lying simplex, sunburn, pruritus in the genital area, alopecia areata, hypertrophic scars, discoid lupus follicular and extensive pyoderma, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin diseases; Diseases that are based on an excessive release of TNF and leukotrienes, such as diseases from bronchitis, allergic Bronchitis
  • Another object of the invention is a method for the treatment of mammals, including humans, who are suffering from one of the abovementioned diseases.
  • the method is characterized in that the sick mammal is administered a therapeutically effective and pharmacologically acceptable amount of one or more of the compounds according to the invention.
  • the invention further relates to the compounds according to the invention for use in the treatment and / or prophylaxis of the diseases mentioned.
  • the invention also relates to the use of the compounds according to the invention for the production of medicaments which are used for the treatment and / or prophylaxis of the diseases mentioned.
  • the invention furthermore relates to medicaments for the treatment and / or prophylaxis of the diseases mentioned, which contain one or more of the compounds according to the invention.
  • the pharmaceuticals are produced by methods known per se and familiar to the person skilled in the art.
  • auxiliaries which are suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
  • solvents for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters can be used.
  • the compounds according to the invention are preferably also administered by inhalation.
  • these are administered either directly as a powder (preferably in micronized form) or by atomizing solutions or suspensions containing them.
  • atomizing solutions or suspensions containing them are administered either directly as a powder (preferably in micronized form) or by atomizing solutions or suspensions containing them.
  • the compounds according to the invention are used in particular in the form of those medicaments which are suitable for topical application.
  • suitable pharmaceutical formulations include, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions.
  • the pharmaceuticals according to the invention are produced by methods known per se.
  • the active ingredients are dosed in the order of magnitude customary for PDE inhibitors.
  • topical forms of application such as ointments
  • the dose for inhalation is usually between 0.01 and 1 mg per spray.
  • the usual dose for systemic therapy po or iv is between 0.1 and 200 mg per application.
  • Activation of inflammatory cells is of particular importance when studying PDE IV inhibition at the cellular level.
  • An example is the FMLP (N-formyl-methionyl-leucyl-phenylalanine) -induced superoxide production of neutrophil granulocytes, which can be measured as luminol-enhanced chemiluminescence.
  • FMLP N-formyl-methionyl-leucyl-phenylalanine
  • Substances which inhibit chemiluminescence and the cytokine secretion and the secretion of inflammation-increasing mediators on inflammatory cells are those which inhibit PDE IV.
  • This isoenzyme of the phosphodiesterase families is particularly represented in granulocytes. Its inhibition leads to an increase in the intracellular cyclic AMP concentration and thus to the inhibition of cellular activation.
  • the PDE IV inhibition by the substances according to the invention is thus a central indicator for the suppression of inflammatory processes.
  • the activity test was carried out according to the Bauer and Schwabe method, which was adapted to microtiter plates (Naunyn-Schmiedeberg's Arch. Pharmacol. 311, 193-198, 1980).
  • the PDE reaction takes place in the first step.
  • the resulting 5'-nucleotide is cleaved by a 5'-nucleotidase of the snake venom from ophiophagus hannah (King Cobra) to the uncharged nucleoside.
  • the nucleoside is separated from the remaining charged substrate on ion exchange columns. The columns are eluted with 2 ml of 30 mM ammonium formate (pH 6.0) directly in minivials, into which 2 ml of scintillator liquid is added for counting.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les composés de la formule (I) où R1, R2, R3, R4, R5 et n ont la signification donnée dans la description, ces composés étant de nouveaux médicaments à visée bronchiale efficaces.
EP97952758A 1996-11-12 1997-11-05 (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase Ceased EP0941226A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97952758A EP0941226A1 (fr) 1996-11-12 1997-11-05 (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19646503 1996-11-12
DE19646503 1996-11-12
EP96118414 1996-11-16
EP96118414 1996-11-16
PCT/EP1997/006131 WO1998021207A1 (fr) 1996-11-12 1997-11-05 (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase
EP97952758A EP0941226A1 (fr) 1996-11-12 1997-11-05 (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase

Publications (1)

Publication Number Publication Date
EP0941226A1 true EP0941226A1 (fr) 1999-09-15

Family

ID=26031178

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97952758A Ceased EP0941226A1 (fr) 1996-11-12 1997-11-05 (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase

Country Status (5)

Country Link
US (1) US6043263A (fr)
EP (1) EP0941226A1 (fr)
JP (1) JP2001504462A (fr)
AU (1) AU5652698A (fr)
WO (1) WO1998021207A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CZ20031334A3 (cs) 2000-11-14 2003-09-17 Altana Pharma Ag Isochinolinové deriváty a jejich použití jako inhibitory
AU2002224835A1 (en) * 2000-11-14 2002-05-27 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Dihydroisoquinolines as novel phosphodiesterase inhibitors
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
CN1646118A (zh) * 2002-03-29 2005-07-27 中外制药株式会社 预防或治疗呼吸系统疾病的药物组合物
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
KR20260027149A (ko) * 2023-05-18 2026-02-27 엔베다 테라퓨틱스, 인크. G 단백질 결합 수용체 길항제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2074933C (fr) * 1990-11-30 2002-12-03 Masatoshi Chihiro Derives du thiazole comme inhibiteur actif du radical superoxyde
AU657413C (en) * 1992-05-29 2007-05-03 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives for the release of superoxide radical
US5639770A (en) * 1992-05-29 1997-06-17 Otsuka Pharmaceutical Co., Ltd. Thiazole derivatives
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
NZ257955A (en) * 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
DK0772610T3 (da) * 1994-07-22 2001-01-29 Byk Gulden Lomberg Chem Fab Dihydrobenzofuraner

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9821207A1 *

Also Published As

Publication number Publication date
JP2001504462A (ja) 2001-04-03
AU5652698A (en) 1998-06-03
US6043263A (en) 2000-03-28
WO1998021207A1 (fr) 1998-05-22

Similar Documents

Publication Publication Date Title
EP0828728B1 (fr) Dihydrobenzofuranes de phenyle
DE69809754T2 (de) Substituierte 6-phenylphenanthridine
DE69717827T2 (de) Benzofuran-4-carboxamide
DE69822162T2 (de) Neue tetrazolderivate
EP0772610B9 (fr) Dihydrobenzofurane
EP0920426B9 (fr) Nouveaux derives de thiazol a effet inhibant la phosphodiesterase
EP0706513B1 (fr) Nouveaux benzamides a substituants fluoroalcoxy et leur utilisation comme inhibiteurs de la phosphodiesterase nucleotidique cyclique
EP0941226A1 (fr) (2,3-dihydrobenzofuranyl)-thiazoles utilises comme inhibiteurs de la phosphodiesterase
WO1998008830A1 (fr) Nouveaux derives de thiazol s'utilisant comme inhibiteurs selectifs de la pde-iv
DE69719358T2 (de) Substituierte dihydrobenzofurane als pde-hemmstoffe
EP0828727B1 (fr) Dihydrobenzofuranes de cyclohexyle
EP1086096B1 (fr) Benzamides avec des substituants tetrahydrofuranyloxy utilises comme inhibiteurs de la phosphodiesterase 4
DE69821530T2 (de) Dihydrobenzifurane
EP1109810B1 (fr) N-oxydes de benzonaphthyridine possedant une activite anti-pde3 et anti-pde4
DE69817548T2 (de) Tetrazole derivate
DE60019894T2 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
DE69808099T2 (de) Substituierte 6-alkylphenanthridine
DE60025327T2 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DE60020079T2 (de) Phenanthridin-N-oxide mit PDE-IV-hemmender Wirkung
DE69916066T2 (de) Neue benzoxazole mit pde-hemmender wirkung
DE60108758T2 (de) 6-heteroarylphenanthridine
EP0819688A1 (fr) Benzofurannes 4-substituées
DE69717277T2 (de) Imidazopyridine
WO1998008844A1 (fr) Nouveaux derives de thiazol s'utilisant comme inhibiteurs selectifs de la pde-iv
EP0937075B1 (fr) Nouvelles Imidazo- et Oxazolopyridines comme inhibiteurs de la Phosphodiesterase.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990614;LT PAYMENT 19990614;LV PAYMENT 19990614;RO PAYMENT 19990614;SI PAYMENT 19990614

17Q First examination report despatched

Effective date: 20020325

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALTANA PHARMA AG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ULRICH, WOLF-RUEDIGER

Inventor name: BAER, THOMAS

Inventor name: BEUME, ROLF

Inventor name: KLEY, HANS-PETER

Inventor name: HAEFNER, DIETRICH

Inventor name: BOSS, HILDEGARD

Inventor name: HATZELMANN, ARMIN

Inventor name: GOEBEL, KARL-JOSEF

Inventor name: GUTTERER, BEATE

Inventor name: FLOCKERZI, DIETER

Inventor name: MARTIN, THOMAS

Inventor name: AMSCHLER, HERMANN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NYCOMED GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070707